This change in ACS guidelines would allow approximately 21 million people more to have access to colorectal cancer screening.
In our opinion, the best evidence still supports screening with Pap and hr-HPV together to provide the best protection against cervical cancer for women ages 30 to 65.
Quest Diagnostics and Thermo Fisher have teamed up to make the Oncomine Dx Target Test broadly accessible nationwide.
USPSTF Considering Changes to Cervical Cancer Screening Guidelines That May Increase Risk of a Missed Diagnosis
FORCE is devoted to supporting women who may be at increased risk for breast and ovarian cancer and for men who are at increased risk for hereditary cancer.
New commercial highlights the abilities of IBM Watson Genomics from Quest Diagnostics for clinicians and patients, no matter where they are.
IBM Watson Genomics from Quest Diagnostics combines genomic sequencing expertise with Watson-powered cognitive computing to inform precision treatment and clinical trial options for cancer patients.
Prostate cancer is the seconding leading cause of cancer death in U.S. men, but if diagnosed early, the five-year survival rate is almost 100 percent.